Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FTAI Aviation Ltd (FTAI) vs Gilead Sciences, Inc. (GILD) Price & Performance

FTAI Aviation LtdTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

FTAI Aviation Ltd vs Gilead Sciences, Inc. — how do they compare? FTAI Aviation Ltd trades at $229.15 (market cap $23.17B), while Gilead Sciences, Inc. trades at $136.65 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 7.3× FTAI Aviation Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

FTAIGILD
Market Cap
$23.17B$168.35B
Sector
IndustrialsHealth
52-Week High
$310.04$155.80
52-Week Low
$140.40$110.56
Enterprise Value
$26.29B$191.42B
Dividend Yield
0.89%2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FTAI Aviation Ltd

FTAI Aviation trades at $229.92, up 6.94% today, with a neutral technical signal and bearish moving averages. Recent earnings missed expectations for three consecutive quarters, though revenue grew to $2.51B in 2025. The company announced a strategic investor relations transition and a significant $1.465B turbine order, signaling operational momentum. Valuation ratios remain elevated, with a P/E of 49.26 and P/B of 57.36, reflecting high growth expectations.

The outlook is mixed: strong analyst consensus (100% buy ratings, $341.67 target) and institutional accumulation support upside, but earnings misses and declining net margins pose risks. Key opportunities include power segment growth and data center demand, while execution on guidance and profitability trends are critical watchpoints for investors.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD